4-((1,3-dioxo-1H-inden-2(3H)-ylidene)methylamino)benzenesulfonamide | 329207-57-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 4-((1,3-dioxo-1H-inden-2(3H)-ylidene)methylamino)benzenesulfonamide
• 英文别名: 4-[(1,3-dioxoinden-2-ylidene)methylamino]benzenesulfonamide
• CAS: 329207-57-0
• 化学式: C₁₆H₁₂N₂O₄S
• 分子量: 328.348
• InChiKey: MRTHTNLWYIMWGC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.71
• 重原子数：
  23.0
• 可旋转键数：
  3.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  106.33
• 氢给体数：
  2.0
• 氢受体数：
  5.0

反应信息

• 作为产物：
  描述：

  1,3-茚满二酮 、 磺胺 、 原甲酸三乙酯 以 乙醇 为溶剂， 反应 3.0h， 以90.5%的产率得到4-((1,3-dioxo-1H-inden-2(3H)-ylidene)methylamino)benzenesulfonamide
  参考文献：
  名称：

  Synthesis and carbonic anhydrase inhibitory properties of 1,3-dicarbonyl derivatives of methylaminobenzene-sulfonamide

  摘要：

  1,3-Dicarbonyl derivatives of methylaminobenzene-sulfonamide were synthesized and their inhibitory effects on the activity of purified human carbonic anhydrase (hCA) I and hCA II were evaluated. hCA I and hCA II from human erythrocytes were purified by a simple one-step procedure by using Sepharose 4B-L-tyrosine-sulfanilamide affinity column. Our results show that the synthesized compounds inhibited the activity of carbonic anhydrase (CA) I and CA II. Among them, 2b and 2e were found to be the most active (IC50 = 2.12 and 2.52 mu M) for hCA I and hCA II, respectively.

  DOI：

  10.3109/14756366.2012.757603

文献信息

• Compounds for Modulating Integrin CD11B/CD18
  申请人：The General Hospital Corporation

  公开号：US20140303026A1

  公开（公告）日：2014-10-09

  The application describes an assay for the identification of small molecule modulators of integrin CD11b/CD18 and small molecules capable of modulating activity of this receptor. Such compounds may be used in certain embodiments for treating a disease or condition selected from inflammation, immune-related disorders, cancer, ischemia-reperfusion injury, stroke, neointimal thickening associated with vascular injury, bullous pemphigoid, neonatal obstructive nephropathy, and cardiovascular disease, or in other embodiments for the treatment of a disease or condition selected from immune deficiency, acquired immune deficiency syndrome (AIDS), myeloperoxidase deficiency, Wiskott-Aldrich syndrome, chronic granulomatous disease, hyper-IgM syndromes, leukocyte adhesion deficiency, Chediak-Higashi syndrome, and severe combined immunodeficiency.
• [EN] COMPOUNDS FOR MODULATING INTEGRIN CD11B/CD18<br/>[FR] COMPOSÉS POUR MODULER L'INTÉGRINE CD11B/CD18
  申请人：PARTNERS HEALTHCARE RES VENTUR

  公开号：WO2008082537A2

  公开（公告）日：2008-07-10

  [EN] The application describes an assay for the identification of small molecule modulators of integrin CDl lb/CD18 and small molecules capable of modulating activity of this receptor. Such compounds may be used in certain embodiments for treating a disease or condition selected from inflammation, immune-related disorders, cancer, ischemia-reperfusion injury, stroke, neointimal thickening associated with vascular injury, bullous pemphigoid, neonatal obstructive nephropathy, and cardiovascular disease, or in other embodiments for the treatment of a disease or condition selected from immune deficiency, acquired immune deficiency syndrome (AIDS), myeloperoxidase deficiency, Wiskott-Aldrich syndrome, chronic granulomatous disease, hyper-IgM syndromes, leukocyte adhesion deficiency, Chediak-Higashi syndrome, and severe combined immunodeficiency.
  [FR] L'invention décrit un essai pour l'identification de modulateurs petites molécules de l'intégrine CD11b/CD18 et de petites molécules capables de moduler l'activité de ce récepteur. De tels composés peuvent être utilisés dans certains modes de réalisation pour traiter une maladie ou un état choisi parmi une inflammation, des troubles immunitaires, un cancer, une lésion d'ischémie-reperfusion, un accident cérébro-vasculaire, un épaississement néointimal associé à une lésion vasculaire, une pemphigoïde bulleuse, une néphropathie obstructive néonatale et une maladie cardio-vasculaire, et dans d'autres modes de réalisation pour le traitement d'une maladie ou d'un état choisi parmi une déficience immunitaire, le syndrome de l'immunodéficience acquise (SIDA), une déficience de la myéloperoxidase, le syndrome de Wiskott-Aldrich, une granulomatose septique chronique, des syndromes hyper-IgM, une déficience de l'adhésion des leucocytes, le syndrome de Chediak-Higashi et une immunodéficience combinée sévère.
• [EN] METHODS AND ANTIBODIES FOR MODULATION OF IMMUNORESPONSE<br/>[FR] MÉTHODES ET ANTICORPS POUR MODULER UNE RÉPONSE IMMUNITAIRE
  申请人：LU YEN-TA

  公开号：WO2016197974A1

  公开（公告）日：2016-12-15

  Provided are an anti-CD11b antibody or an antigen-binding portion thereof, and methods and use of the antibody for modulating immunoresponses by regulating CD11b expression on cells